New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Phase 3 Study initiating in First Quarter of 2026Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration ...

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

Cullinan Therapeutics (CGEM) and Otsuka Holdings (OTSKF) subsidiaries Taiho Oncology and Taiho Pharmaceutical have initiated the rolling ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies (CAPS) and their colleagues have made a ...

Researchers at Tulane University, with a team of colleagues from eight other universities, have discovered a new nerve cell ...